The emerging role of metabolic regulation in the functioning of Toll-like receptors and the NOD-like receptor Nlrp3  by Tannahill, Gillian M. & O’Neill, Luke A.J.
FEBS Letters 585 (2011) 1568–1572journal homepage: www.FEBSLetters .orgReview
The emerging role of metabolic regulation in the functioning of Toll-like
receptors and the NOD-like receptor Nlrp3
Gillian M. Tannahill ⇑, Luke A.J. O’Neill
School of Biochemistry and Immunology, Trinity College Dublin, Ireland
a r t i c l e i n f o a b s t r a c tOpen access under CC BY-NC-ND license.Article history:
Received 12 April 2011
Revised 29 April 2011
Accepted 2 May 2011
Available online 6 May 2011







Insulin resistance0014-5793  2011 Published by Elsevier B.V. on beh
doi:10.1016/j.febslet.2011.05.008
⇑ Corresponding author.
E-mail addresses: tannahig@tcd.ie (G.M. Tann
O’Neill).While it has long been suspected that inﬂammation participates in the pathogenesis of metabolic
disorders such as the insulin resistance that occurs in type 2 diabetes, recent work suggests that this
is not the only important interaction between metabolism and inﬂammation. Inroads into the
understanding of the relationship between metabolic pathways and inﬂammation are indicating
that signaling by innate immune receptors such as TLR4 and Nlrp3 regulate metabolism. TLRs have
been shown to promote glycolysis, whilst Nlrp3-mediated production of IL-1b causes insulin resis-
tance. A key role for the hypoxia-sensing transcription factor HIF1a in the functioning of macro-
phages activated by TLRs has also recently emerged. This review will assess recent evidence for
these complex interactions and speculate on their importance for innate immunity and
inﬂammation.
 2011 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Innate immune system acts as the ﬁrst line of defense against
infection partly by recognising highly conserved sets of molecular
targets called pathogen-associated molecular patterns (PAMPs) via
a limited number of germline-encoded receptors known as pat-
tern-recognition receptors (PRRs). These PRRs include Toll-like
receptors (TLRs) and NOD-like receptors (NLRs), both of which ini-
tiate downstream signaling pathways that culminate in the activa-
tion of antimicrobial pro-inﬂammatory immune responses.
TLRs recognise speciﬁc components of viruses, bacteria, fungi
and parasitic protozoa. In mammals 12 members of the TLR family
have been identiﬁed. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are
expressed on the cell surface of various immune cells, whereas
TLR3, TLR7, TLR8 and TLR9 are expressed in intracellular compart-
ments such as the endoplasmic reticulum and endosomes. TLR4,
the best characterised TLR, is highly expressed on dendritic cells
(DCs) and macrophages and binds to lipopolysaccharides (LPS)
from Gram-negative bacterial cell walls. All TLRs are type I trans-
membrane receptors, characterized by an extracellular leucine rich
repeat (LRR) domains and an intracellular Toll-IL1 receptor-Resis-
tance (TIR) domain. The TIR domain is necessary for the recruit-
ment of various adaptor molecules to activate the downstreamalf of the Federation of European B
ahill), laoneill@tcd.ie (L.A.J.signaling pathways, such as those that activate NF-kappaB (NF-
jB), leading to the transcription of typical pro-inﬂammatory cyto-
kines such as interleukin-1 beta (IL-1b), interleukin 6 (IL-6) and tu-
mor necrosis factor alpha (TNFa) [1].
NLRs are involved in the recognition of host-derived and micro-
bial ‘danger’ associated molecules which are produced under con-
ditions of cellular stress or injury. Activation of a subset of NLRs
leads to the assembly of high-molecular-mass complexes called
inﬂammasomes. There are currently four inﬂammasomes identi-
ﬁed, comprising NLRP3, NLRP1, NLRC4 and AIM2. Inﬂammasome
activation has been shown to lead to the generation of active cas-
pase 1, a requisite for the production of the mature form of the
archetypal inﬂammatory cytokine, IL-1b [2] .
Recently, evidence has emerged that both TLRs and inﬂamma-
somes impact on metabolism. TLR activation leads to the so-called
‘Warburg effect’, involving a switch to glycolysis, similar to that
occurring in tumors [3]. The NLRP3 inﬂammasome on the other
hand has been shown to cause insulin insensitivity and may be
important for the pathogenesis of type 2 diabetes (T2D) [4]. In this
review we discuss these recent ﬁndings and present a model
whereby metabolic regulation in the TLR and NLRP3 systems might
be a key controlling process in innate immunity. This area is a new
and exciting frontier in the role of innate immunity in the sensing
of metabolic imbalance, as would occur in infection and tissue in-
jury. This process could be critical for the restoration of homeosta-
sis following such insults.iochemical Societies. Open access under CC BY-NC-ND license.
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function
Generally it is understood that mammalian cells acquire energy
in the form of ATP by anaerobic glycolysis when oxygen is limiting
or oxidative phosphorylation when oxygen is available. Whilst the
aerobic pathway may provide more energy per glucose molecule
(32 ATP) it is relatively slow. Glycolysis on the other hand only pro-
duces 2 ATP per glucose molecule, but it can do so very rapidly. It is
this response that may be vital for immune cells such as macro-
phages and DCs in hypoxic environments such as those encoun-
tered at sites of inﬂammation. In support of this there is
evidence to suggest that both macrophages and dendritic cells
(DCs) require the glycolytic pathway not only for rapid energy
metabolism but importantly for immune function.
Mounting an immune response to infection is energy intensive.
In the presence of pathogens or pathogen products, immune cells
can shift from quiescence to a highly active state within hours of
stimulation. Recent data has shown that DCs can do this by switch-
ing their core metabolism from oxidative phosphorylation to gly-
colysis [3]. Whilst resting DCs predominantly use the more
conservative catabolic program of oxidative phosphorylation, TLR
sensing activates the switch to glycolysis. DCs stimulated with
multiple TLR agonists up-regulate Glucose transporter 1 (GLUT1)
expression, have increased lactate production and a decrease in
mitochondrial O2 consumption, all hallmarks of glycolysis [3,5].
Importantly it was shown that this is mediated by the PI3K/Akt
pathway, as DCs lacking Akt1 or treated with the PI3K inhibitor
LY294002 exhibited signiﬁcantly reduced LPS-induced glycolysis.
In contrast, DC retrovirally transduced to express an active form
of Akt had increased background levels of glycolysis and an in-
creased glycolytic response to LPS. Interestingly, the suppression
of mitochondrial fatty acid b-oxidation triggered by LPS was unaf-
fected by the inhibition of PI3K by LY294002, the absence of Akt1,
or the expression of the active form of Akt. Instead AMP kinase
(AMPk), a central regulator of catabolic metabolism and oxidative
phosphorylation in eukaryotic cells appears to be responsible for
the energy production by oxidative phosphorylation in resting
DCs, as reduction in AMPk levels boosted LPS-induced glycolysis
[3]. This shift in metabolism is not only necessary for the viability
and maturation of DCs but supports the development of demand-
ing cellular functions including the transcription, translation and
secretion of an array of inﬂammatory mediators.
DCs are however not the only immune cells reliant on glycoly-
sis. Macrophages are also highly dependent on glycolysis for the
production of ATP. Addition of glycolytic inhibitors reduces activity
of these myeloid cells whereas mitochondrial inhibitors have not
been shown to affect their ability to mount an inﬂammatory re-
sponse [6]. In addition to generating ATP quickly to meet cellular
demands, increasing glycolysis has also been shown to protect
activated macrophages from apoptosis [7]. Activation of macro-
phages by interferon gamma (IFNc) and LPS inhibits mitochondrial
respiration. This is caused by release of large quantities of nitric
oxide (NO) produced by the inducible NO synthase, consequently
arresting oxidative phosphorylation and preventing mitochondrial
ATP production [8]. Ordinarily this would cause mitochondrial col-
lapse and apoptotic cell death but macrophages are able to remain
viable and functional due to the switch to glycolysis. ATP produced
by increased glycolysis is consumed by the mitochondria to main-
tain the mitochondrial membrane potential [7] .Glycolysis is there-
fore necessary for both activation of cells and protection from cell
death and helps explain how macrophages can survive and func-
tion in oxygen deprived environments.
The molecular basis of increased glycolysis in response to TLR
activation is poorly understood but a recent study highlights theimportance of the bifunctional isoenzyme 6-phosphofructo-2-ki-
nase/fructose-2,6-biphosphatase (PFK2) [9]. PFK2 catalyses the
synthesis and degradation of fructose 2,6-bisphosphate (Fru-2,6-
P2), which is the most potent activator of 6-phosphofructo-1-ki-
nase, a key regulatory enzyme in glycolysis. Two isoforms of
PFK2 exist, L-PFK2 which is expressed in the liver, is less active
and causes degradation of Fru-2,6-P2, and the more active ubiqui-
tous form, u-PFK2 which increases synthesis of Fru-2,6-P2. Activa-
tion through multiple TLR pathways causes a preferential shift to
the u-PFK2 isoform, with L-PFK2 protein levels almost undetect-
able. Expression of u-PFK2 caused an increase in the conversion
of glucose to lactate, whilst attenuation of uPFK2 expression im-
paired macrophage viability upon activation [9]. Together these
data suggest a direct link between TLR activation and glycolysis.
3. HIF is induced by LPS
Another mechanism that could link LPS and TLR4 to enhanced
glycolysis is the transcription factor HIF1alpha (HIF1a) [10]. Hy-
poxia-inducible factor (HIF) is the principle transcriptional regula-
tor of hypoxic adaption and directs cells to produce ATP via
glycolysis [11].
HIF consists of a constitutively active b-subunit and an oxygen
labile a-subunit, which exists in three forms termed HIF1a, -2a
and -3a. In the presence of oxygen HIF1a protein is rapidly turned
over. Conserved proline residues of HIF1a are hydroxylated by a
family of three prolyl hydroxylases (PHD1-3) [12]. This allows rec-
ognition by an E3 ubiquitin ligase containing the von Hippel-Lin-
dau (VHL) protein which leads to ubiquitin-mediated targeting of
HIF1a for proteasomal destruction [13]. In addition, a conserved
asparagine residue of HIF1a undergoes hydroxylation by Factor
Inhibiting HIF (FIH) in the presence of oxygen. This asparaginyl
hydroxylation prevents recruitment of co-activators to the HIF
complex, thereby preventing downstream target gene transcrip-
tional activation [14,15]. In hypoxic conditions reactive oxygen
species (ROS) produced by the mitochondria induce H202-medi-
ated HIF1a expression by targeting PHD. Hydrogen peroxide
(H2O2) oxidises Fe2+ to Fe3+, reducing Fe availability which is re-
quired by PHD to hydroxylate HIF1a. These data show that lack
of mitochondrial respiration increases expression of HIF1a. When
degradation of HIF1a is prevented it translocates to the nucleus,
binds HIF1b and other co-activators and initiates transcription of
target genes which contain conserved Hypoxia Response Elements
(HRE), [16] including those involved in glycolysis, erythropoiesis,
angiogenesis and proliferation.
HIF1a is transcriptionally induced by LPS and is required to con-
trol multiple myeloid cell functions [5,17–19]. Several signaling
intermediates have been reported to be involved, including NF-
jB [20,21], ROS [22–24], PHD [18] and p42/p44 mitogen-activated
protein kinases (MAPKs) [20].
LPS induces HIF1a mRNA expression in human monocytes
through NF-jB binding to the promoter of the HIF1a gene
[20,21]. Inhibitor of NF-jB (IjB) kinases, responsible for activation
of NF-kB, are also critical in the upregulation of HIF1a expression
as macrophages deﬁcient in IKK-b (b subunit of IjB) have de-
creased expression of the HIF1a target, GLUT1 [21]. In addition,
LPS- induced HIF1a was accompanied by a signiﬁcant increase in
phosphorylation of the MAP kinase intermediate p44/42. Activa-
tion of p44/42 appears to be critical for LPS-induced HIF1a activa-
tion, since inhibition of the upstream kinase MEK1/2 by PD 98059
and RNAi directed against p44/42 signiﬁcantly reduced HIF1a
mRNA and protein accumulation [20].
Other studies indicate that HIF1a induction by LPS is dependent
on ROS generation [23,24]. Wang et al. demonstrated that young
Mclk1+/- mice (Mclk1 encodes a mitochondrial protein necessary
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and mitochondrial function but sustained mitochondrial oxidative
stress. LPS treatment of these mice led to an increase in HIF1a
expression and elevation of levels of pro-inﬂammatory cytokines
[23]. Sphingosine kinase 1 (SphK1) has also recently been shown
to mediate LPS-induced ROS activation of HIF1a. Extracellular sig-
nal-regulating kinase, PLC-1c and PI3 Kinase were found to be crit-
ical for the LPS-induced SphK1 activation [22].
Additionally, it has been shown that LPS increases HIF1a pro-
tein accumulation through decreasing the transcription of PHD2
and PHD3 in macrophages in a TLR4-dependent manner [18].
HIF1a directly binds to the promoter of the TLR4 locus and up-reg-
ulates TLR4 expression during O2 deprivation [10].
HIF1a up-regulates the expression of several glycolytic en-
zymes but there is also evidence to suggest glycolysis controls
HIF1a expression. Culturing various normal and tumor cell lines
in glucose, lactate or pyruvate (end products of glycolysis) in-
creases HIF1a levels. Pyruvate, which was shown to be the most
potent inducer, also promotes HIF1a DNA- binding and increases
transcription of vascular endothelial growth factor (VEGF), eryth-
ropoietin (EPO), GLUT3, aldolase A [25] and plasminogen activator
inhibitor-1 (PAI-1) [26] indicating that glycolysis-induced HIF1a is
functional However a mechanism of pyruvate-regulated HIF1a
expression has yet to be determined.
The mitochondrial tricarboxylic acid cycle (TCA) links glycolysis
and oxidative phosphorylation. By manipulating the rate limiting
enzyme, succinate dehydrogenase (SDH) which converts succinate
to fumerate in the TCA cycle, HIF1a expression can be enhanced
[27]. Succinate directly inhibits PHD activity by product inhibition,
since PHD also converts alpha-ketoglutarate to succinate. Also,
blocking glycolysis with 2-Deoxyglucose (2DG) causes an increase
in succinate dehydrogenase activity, decreasing succinate, which
in turn enhances PHD activity leading to degradation of HIF1a.
Addition of succinate also increases ROS production and rescues
HIF1a protein expression and transcriptional activity. 2DG thereby
causes increased turnover of HIF1a. Succinate also rescued the ef-
fect of 2DG on HIF1a expression [27]. These data highlight the bal-
ance required between glycolysis and oxidative phosphorylation to
regulate HIF1a expression.Fig. 1. Interplay between TLR4, glycolysis and HIF1a. Activated DCs and macrophages sh
cellular function. HIF1a is a key regulator of the expression of glycolytic enzymes. Its reg
is less well understood, however TLR4 signalling and glycolysis may play an importantThe stabilisation of HIF1a by glucose may also involve the pen-
tose phosphate pathway (PPP) rather than glycolysis [28]. The PPP
pathway generates reducing equivalents, in the form of NADPH, for
reductive biosynthetic reactions Treatment of a mast cell line HMC
with the PPP inhibitor 6-aminonicotinamide (6-AN) prevented the
glucose induced stabilisation of HIF1a. Addition of NAPDH en-
hanced HIF1a protein expression whereas silencing glucose-6-
phosphate dehydrogenase, the rate-limiting enzyme responsible
for NAPDH, prevented HIF1a stabilisation [28]. Glucose metabo-
lism is clearly necessary for the stabilization of HIF1a, but it is
yet to be determined which metabolite(s) is responsible. Since
TLRs promote glycolysis, it is likely that the PPP is also enhanced,
which could impact on HIF1a stability.
These data support an inter-dependent relationship between
HIF1a and LPS resulting in positive feedback which may amplify
macrophage activity at sites of hypoxia and infection (Fig. 1).
4. HIF is essential for myeloid function
HIF seems to be critical in innate cell development and function
as it is required for DC and macrophage maturation [3,5,29,30].
Knocking down HIF decreases the ability of the DC to up-regulate
co-stimulatory factors and reduces the potential of DCs to stimu-
late the proliferation of allogenic T cells [5]. In mice with mye-
loid-speciﬁc ablation of the HIF1a subunit, HIF1a deﬁciency
results in an 80% reduction of ATP [31]. The metabolic defect in
HIF1a deletion in macrophages results in impairment of energy-
demanding processes such as aggregation, migration and invasion
[31]. In addition to its key role in regulating metabolism and en-
ergy generation, Cramer et al. showed that HIF1amediates macro-
phage inﬂammatory responses. Compared to control mice, myeloid
HIF1a-/- mice displayed reduced acute skin inﬂammation trig-
gered by 12-O-tetradecanoylphorbol-13-acetate (TPA), as indi-
cated by decreased edema and leukocyte inﬁltration [31]. When
induced to develop arthritis, these mice also showed compromised
synovial inﬁltration, pannus formation and cartilage destruction,
suggesting ameliorated chronic inﬂammatory responses mediated
by HIF1a deﬁcient macrophages. In addition, in patients, HIF1a
was shown to be abundantly expressed by macrophages inift their metabolism to glycolysis for energy and biosynthesis to support demanding
ulation by hypoxia is well known but how it is regulated under normoxic conditions
role.
?Fig. 2. TLR4, Nlrp3, hyperglycemia and hyperlipidemia in IL-1b production. TLR4
and Nlrp3 act in concert to produce the pro-inﬂammatory cytokine IL-1b. TLR4 will
promote glucose uptake which is metabolised by glycolysis. An increase in
succinate may occur (although precisely how is unknown), inhibiting PHD,
stabilising HIF1a which could have a role in the induction of pro-IL-1b. In addition,
succinate can induce ROS, which also decreases PHD activity, but in addition are
required for Nlrp3 inﬂammasome activation. The source of the ROS appears to be
mitochondria. Hyperlipidemia will generate lipids such as ceramides and palmitate,
which also activate Nlrp3, as does IAPP deposited in the pancreas in type 2 diabetes.
Nlrp3 activates caspase-1 leading to production of IL-1beta, which acts in a negative
feedback manner to block insulin signaling and glucose uptake. These events may
be critical in the pathogenesis of type 2 diabetes.
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via [32]. In infection models, loss of myeloid HIF1a resulted in de-
creased bacterial killing of group A. Streptococcus and P. aeruginosa
by macrophages in vitro and in vivo [33]. Furthermore, exposure to
these pathogens and LPS induced HIF1a activity in macrophages in
a TLR4-dependent fashion [18].
Loss of HIF1a in macrophages led to signiﬁcant decreases in the
production of TNFa, IL-1b and IL-1a, but not IFNc or the anti-
inﬂammatory cytokines IL-4 and IL-10. Therefore HIF1a appears
to be necessary for the transcription of proinﬂammatory cytokines
[18]. This identiﬁes proinﬂammatory cytokines as potential HIF
target genes.
5. Inhibition of glycolysis by caspase 1
In a manner opposite to TLRs, the NLRC4 inﬂammasome might
actually inhibit glycolysis. As glycolysis is essential for macrophage
survival and activation, the cleavage of glycolytic enzymes is there-
fore predicted to be an essential step toward cell death. Indeed it’s
been shown that the glycolytic enzymes, fructose-bisphosphate
aldolase, glyceraldehyde-3-phosphate dehydrogenase, a-enolase
and pyruvate kinase can be speciﬁcally targeted by active caspase
1. These enzymes were processed in peritoneal macrophages from
wild type mice infected with S. Typhimurium, but not in those lack-
ing caspase 1 [34]. Since NLRC4 senses S. Typhimurium to activate
caspase-1, this implicates the NLRC4 inﬂammasome in this process
[35]. In addition, the rate of glycolysis in the caspase 1 deﬁcient
cells was higher, further supporting the inhibitory role for caspase
1-mediated inactivation of glycolytic enzymes [34]. These data
provide evidence that inﬂammasomes inhibit glycolysis. This
may therefore restrict intracellular pathogen replication by deplet-
ing energy stores quickly and allowing the infected host to undergo
caspase 1-mediated cell death.
6. Inﬂammation and metabolic disorders
Glycolysis is clearly important for DC and macrophage function.
High glucose levels however can have adverse effects. Chronichyperglycemia associated with over nutrition leads to insulin resis-
tance. Insulin is secreted by pancreatic beta cells (b cells) and pro-
motes glucose uptake in the muscle and reduces gluconeogenesis
in the liver and lipolysis in adipose tissue. Insulin resistance results
in defective nutrient metabolism and glucose intolerance. Eventu-
ally pancreatic beta cells can no longer compensate for insulin
resistance and type 2 diabetes with elevated circulating glucose
develops. Obesity is the fundamental cause of insulin resistance
and type 2 diabetes.
Obesity is characterized by increased storage of Fatty Acids (FA)
in an expanded adipose tissue mass and a state of chronic inﬂam-
mation. Recent evidence suggests that both TLR4 and Nlrp3 are
critical in this process with IL-1beta as the key inﬂammatory cyto-
kine. TLR4 induces pro-IL-1b whilst Nlrp3 activates caspase 1 lead-
ing to production of the mature active cytokine. Adipose tissue has
been viewed upon as the instigator of insulin resistance [36,37].
There is accumulation of macrophages in adipose tissue in obese
patients [38]. This is associated with increased levels of TNFa.
TNFa induces insulin resistance by disrupting insulin signal trans-
duction through the phosphorylation of inhibitory serine of insulin
receptor substrate 1 (IRS1) [39]. Mice lacking functional TNFa are
protected against obesity-induced insulin resistance. In addition,
TNFa is also over-expressed in the adipose and muscle tissues of
obese humans, and when administered exogenously leads to insu-
lin resistance [40]. However, attempts to block TNF signaling in ob-
ese individuals with T2DM have so far yielded disappointing
results [41]. In addition, IL-1b accumulates in adipose tissue and
mediates insulin resistance. Wild type mice injected with IL-1b
have decreased insulin sensitivity compared to IL-1b null mice,
which do not show insulin resistance when fed a high fat diet
[42]. Recent data suggest that Nlrp3 is responsible for sensing
obesity-associated inducers of caspase 1, such as lipotoxic cera-
mides and palmitate, a saturated free fatty acid, to initiate macro-
phage activation and IL-1b secretion [4,42]
Insulin resistance leads to the pancreas over-working to pro-
duce more and more insulin to ‘mop up’ glucose in the blood met-
abolic stress signals recruit monocytes to clear dying b cells.
Increased numbers of macrophages are observed in pancreatic is-
lets from patients with type 2 diabetes [43]. Hyperglycemia in-
duces IL-1b secretion by both macrophages and pancreatic cells
b-cells [44–46] creating an inﬂammatory environment which has
cytotoxic effects on b-cells [45,47] inducing them to undergo apop-
tosis [48]. In b cells, glucose induces ROS generation which subse-
quently activates Nlrp3-dependent IL-1b secretion. This is
mediated by thioredoxin-interacting protein (TXNIP) which di-
rectly binds Nlrp3. This suggests oxidative stress is responsible
for IL-1b secretion in these cells [49]. In macrophages however in
addition to glucose, the amyloid polypeptide (IAPP) which is se-
creted along with insulin in the pancreas, is required for Nlrp3-
dependent IL-1b processing [50]. Glucose also activates caspase 1
in human and murine adipose tissue. Glucose-induced activation
of TXNIP mediates IL-1b mRNA expression levels and intracellular
pro-IL-1b accumulation in adipose tissue [51]. In addition, mice
deﬁcient in either Nlrp3, caspase 1, or IL-1b fed a normal-chow diet
have improved insulin sensitivity, supporting the role of Nlrp3 in
regulating glucose homeostasis [52].
The mechanisms by which IL-1b attenuates insulin signaling in-
clude interactions of IL-1b-dependent signalling proteins with
insulin receptor and/or IRS proteins, such as members the SOCS
family. SOCS1, SOCS3 and SOCS6 have been identiﬁed as the prin-
ciple inhibitors of the insulin pathway by interfering with IRS-1
and IRS-2 phosphorylation or by targeting IRS for proteasomal deg-
radation [53].
Why would the NLRP3/IL-1 system cause insulin resistance?
There are two possibilities. Insulin resistance in the periphery
might spare glucose for leukocyte function in immune cells. Or
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take and metabolism to prevent generation of ROS or other metab-
olites, made as a result of enhanced glucose metabolism (Fig. 2)
which would be damaging.7. Perspective
The interface between metabolism and innate immunity is of
great interest. TLRs and Nlrp3 may sense metabolic disturbance
caused by tissue injury, obesity and infection, and trigger processes
to restore homeostasis. These innate receptors also impact directly
on metabolic events during this process. HIF1a may be especially
important in these pathways and insulin resistance an important
output from the Nlrp3 inﬂammasome. Further molecular details
are needed and where speciﬁcity lies in these events is an impor-
tant question. Future work will reveal the importance of metabolic
processes for inﬂammation in both health and disease.
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